Circulating monoclonal immunoglobulins in Sjogren syndrome -: Prevalence and clinical significance in 237 patients

被引:45
作者
Brito-Zerón, P
Ramos-Casals, M
Nardi, N
Cervera, R
Yagüe, J
Ingelmo, M
Font, J
机构
[1] Univ Barcelona, Hosp Clin Barcelona, Serv Malalties Autoimmunes, Dept Autoimmune Dis,Fac Med, E-08036 Barcelona, Spain
[2] Univ Barcelona, Hosp Clin Barcelona, Fac Med, Dept Immunol, E-08036 Barcelona, Spain
[3] Univ Barcelona, Hosp Clin Barcelona, Fac Med, IDIBAPS, E-08036 Barcelona, Spain
关键词
D O I
10.1097/01.md.0000157398.37679.47
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
We conducted the current study to analyze the prevalence and clinical significance of circulating monoclonal immunoglobulins in patients with Sjogren syndrome (SS), focusing on the association with extraglandular features, immunologic markers, hematologic neoplasia, and hepatitis C virus (HCV) infection. We performed serum immunoelectrophoresis in 200 patients with primary SS and 37 patients with HCV-related SS. All patients fulfilled 4 or more of the 1993 European classification criteria for SS. Of the 200 patients with primary SS, 35 (18%) presented circulating monoclonal immunoglobulins. The monoclonal bands identified were 20 IgG (13 kappa, 7 lambda), 10 IgM (5 kappa, 5 lambda), 2 IgA kappa, and 3 free circulating light chains. Of the 37 SS-HCV patients, 16 (43%) had circulating monoclonal immunoglobulins. The monoclonal bands identified were 10 IgM kappa, 5 IgG lambda, and 1 free light lambda chain. Compared with primary SS patients, SS-HCV patients presented a higher frequency of monoclonal immunoglobulins (43% vs 18%, p = 0.001), with monoclonal IgM kappa being the most frequent monoclonal band. Six (12%) of the 51 SS patients with circulating monoclonal immunoglobulins presented hematologic neoplasia, compared with 3 (1.6%) of those without monoclonal immunoglobulins (p = 0.004; odds ratio = 8.13; 95% confidence intervals, 1.64-51.54). In 2 of the 6 patients with monoclonal immunoglobulins and lymphoproliferative disorders, a change of the monoclonal component was detected in previous immunoelectrophoresis determinations before the development of hematologic neoplasia. Circulating monoclonal immunoglobulins were detected in nearly 20% of patients with primary SS, with monoclonal IgG being the most frequent type of immunoglobulin detected. In SS-HCV patients, the prevalence of monoclonal immunoglobulins was higher (43%), with monoclonal IgM being the most frequent type found. SS-HCV patients presented a more restrictive monoclonal expression (limited to either monoclonal IgM kappa or monoclonal IgG lambda) than primary SS patients, who showed all types of heavy and light chains.
引用
收藏
页码:90 / 97
页数:8
相关论文
共 46 条
[1]
Akashi Y, 1996, NEPHRON, V73, P730
[2]
Andonopoulos AP, 1997, REV RHUM, V64, P287
[3]
Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection [J].
Andreone, P ;
Zignego, AL ;
Cursaro, C ;
Gramenzi, A ;
Gherlinzoni, F ;
Fiorino, S ;
Giannini, C ;
Boni, P ;
Sabattini, E ;
Pileri, S ;
Tura, S ;
Bernardi, M .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (04) :294-298
[4]
SMALL-CELL LYMPHOMA AND SJOGRENS SYNDROME - LYMPHOPLASMACYTIC SUBVARIANT OF SMALL-CELL LYMPHOMA WITH IGA-KAPPA IMMUNOGLOBULIN SURFACE-MARKERS [J].
ASKARI, AD ;
LAQUI, CC ;
RASSIGA, AL ;
HOGREFE, WR ;
LAIPPLY, TC .
ARCHIVES OF INTERNAL MEDICINE, 1985, 145 (05) :935-937
[5]
Ben Ghorbel I, 2003, REV MED INTERNE, V24, P138
[6]
SELECTIVE BONE-MARROW INVOLVEMENT OF LYMPHOPLASMACYTIC CELLS SECRETING MONOCLONAL IGA RHEUMATOID-FACTOR IN A PATIENT WITH SJOGRENS SYNDROME AND SERUM HYPERVISCOSITY [J].
BERGONZI, C ;
MERLINI, GP ;
MORANDI, S ;
BIANCHINI, E ;
PAVESI, F ;
BELLOTTI, V ;
MONTECUCCO, CM ;
ASCARI, E .
ANNALS OF THE RHEUMATIC DISEASES, 1987, 46 (12) :938-942
[7]
FALSE-POSITIVE HEPATITIS-C VIRUS-ANTIBODY TESTS IN PARAPROTEINEMIA [J].
BOUDART, D ;
LUCAS, JC ;
MULLER, JY ;
LECARRER, D ;
PLANCHON, B ;
HAROUSSEAU, JL .
LANCET, 1990, 336 (8706) :63-63
[8]
CASARIL M, 1987, HAEMATOLOGICA, V72, P167
[9]
DANIELS TE, 1992, RHEUM DIS CLIN N AM, V18, P571
[10]
De Re V, 2002, EUR J IMMUNOL, V32, P903, DOI 10.1002/1521-4141(200203)32:3<903::AID-IMMU903>3.0.CO